Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

CureVac N.V. - Ordinary Shares (NQ:CVAC)

4.440 +0.090 (+2.07%)
Streaming Delayed Price Updated: 4:00 PM EDT, May 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CureVac N.V. - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer
Via ACCESSWIRE
CureVac to Present at the 12th International mRNA Health Conference
Via ACCESSWIRE
CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
Via ACCESSWIRE
CureVac's CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress
Via ACCESSWIRE
GSK Reveals 'Positive' Data From Mid-Stage Study Of Seasonal Influenza mRNA Vaccine
GSK announced positive phase 2 trial results for its mRNA seasonal flu vaccine, showing strong immune. 
Via Benzinga
CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program
Via ACCESSWIRE
CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected Glioblastoma
Via ACCESSWIRE
CureVac Announces Financial Results for the Second Quarter and First Half of 2024 and Provides Business Update
Via ACCESSWIRE
CureVac Provides Update on Trial Dates for Patent Litigation Across Multiple Geographies Against Pfizer/BioNTech
Via ACCESSWIRE
CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress
Via ACCESSWIRE
CVAC Stock Earnings: CureVac Misses EPS, Beats Revenue for Q2 2024
CVAC stock results show that CureVac missed analyst estimates for earnings per share but beat on revenue for the second quarter of 2024. 
Via InvestorPlace
CureVac Names Oncologist and Drug Development Expert Dr. Mehdi Shahidi to Supervisory Board
Via ACCESSWIRE
CVAC Stock Earnings: CureVac Misses EPS, Misses Revenue for Q1 2024
CVAC stock results show that CureVac missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. 
Via InvestorPlace
Southwest Airlines Adopts a Poison Pill Plan: 7 Things to Know
Southwest Airlines is in the news Wednesday after the airline company adopted a poison pill to battle activist investor Elliott Management. 
Via InvestorPlace
GSK and CureVac to Restructure Collaboration into New Licensing Agreement
Via ACCESSWIRE
CureVac Announces Financial Results for the First Quarter of 2024 and Provides Business Update
Via ACCESSWIRE
Why Is DouYu (DOYU) Stock Up 44% Today?
DouYu stock is up on Wednesday after the company announced a special cash dividend for DOYU investors payable in August. 
Via InvestorPlace
CureVac Layoffs 2024: What to Know About the Latest CVAC Job Cuts
CureVac layoffs are coming for 30% of the vaccine company's employees as it prepares for a restructuring that will save it over 30% in costs. 
Via InvestorPlace
Topics Workforce
Exposures Layoff
GOEV Stock: Canoo Receives Fleet Order From Go2 Delivery
Canoo stock is down on Wednesday as GOEV investors appear unimpressed by the company's new delivery van fleet deal with Go2 Delivery. 
Via InvestorPlace
DM Stock Alert: Nano Dimension Is Scooping Up Desktop Metal for $183 Million
Desktop Metal stock is up on Wednesday as DM investors learn of an acquisition deal with Nano Dimension for the company's shares. 
Via InvestorPlace
CVAC Stock Alert: CureVac Pops on Licensing Deal With GSK
CureVac stock is up on Wednesday as CVAC investors react to the company signing a new 1.4 billion euro licensing agreement with GSK. 
Via InvestorPlace
GSK Buys Full Rights To Investigational Covid-19 And Influenza Vaccines From CureVac For Around $1.5B
GSK and CureVac restructured their collaboration into a new licensing agreement, prioritizing mRNA vaccine development. GSK gains full control of vaccine candidates for influenza and COVID-19, while... 
Via Benzinga
Exposures COVID-19
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Pre-market stock movers are worth checking out on Wednesday with our breakdown of all the biggest news affecting shares this morning. 
Via InvestorPlace
CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities
Via ACCESSWIRE
CureVac Announces Voting Results of General Meeting
Via ACCESSWIRE
Why Quantum Shares Are Trading Lower By 45%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
First Human Death From Bird Flu Strain Puts Vaccine Stocks Back On The Map
Moderna shares are up almost 29% this month; CureVac is up 72% in the past month; and Novavax spiked 317% in the past month. 
Via Benzinga
Ollie's Bargain Outlet Posts Upbeat Earnings, Joins Verint Systems, Guidewire Software And Other Big Stocks Moving Higher On Wednesday
Via Benzinga
Why Lands' End Shares Are Trading Lower? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Via Benzinga
CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK
Via ACCESSWIRE
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.